A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LA237) 50 mg QD in subjects with impaired glucose tolerance (IGT).

Trial Profile

A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to assess the efficacy and safety of 12 week treatment with vildagliptin (LA237) 50 mg QD in subjects with impaired glucose tolerance (IGT).

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Feb 2015

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Glucose intolerance
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 04 May 2012 Actual patient number is 171 and additional location (USA) added according to ClinicalTrials.gov.
    • 04 May 2012 Actual end date (Jul 2006) added as reported by ClinicalTrials.gov.
    • 04 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top